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Abstract: Cancer is one of the leading causes of human death. Many efforts have
made to understand its mechanism and have further identified many proteins and
DNA  sequence  variations  as  suspected  targets  for  therapy.  However,  drugs
targeting these targets have low success rates, suggesting the basic mechanism
still remains unclear. Here, we develop a computational software combining Cox
proportional-hazards model and stability-selection to unearth an overlooked, yet
the  most  important  cancer  drivers  hidden  in  massive  data  from  The  Cancer
Genome  Atlas  (TCGA),  including  11,574  RNAseq  samples  and  clinic  data.
Generally,  noncoding  RNAs  primarily  regulate  cancer  deaths  and  work  as  the
deadliest cancer inducers and repressors, in contrast to proteins as conventionally
thought.  Especially,  processed-pseudogenes  serve  as  the  primary  cancer
inducers, while lincRNA and antisense RNAs dominate the repressors. Strikingly,
noncoding RNAs serves as the universal strongest regulators for all cancer types
although personal clinic variables such as alcohol and smoking significantly alter
cancer genome. Furthermore, noncoding RNAs also work as central hubs in cancer
regulatory network and as biomarkers to discriminate cancer types.  Therefore,
noncoding RNAs overall serve as the deadliest cancer regulators, which refreshes
the  basic  concept  of  cancer  mechanism  and  builds  a  novel  basis  for  cancer
research  and  therapy.  Biological  functions  of  pseudogenes  have  rarely  been
recognized.  Here we reveal  them as the most important cancer drivers for  all
cancer types from big data, breaking a wall to explore their biological potentials. 
Introduction
Cancer has been a leading cause of  death globally.  In  2018,  more than 609K
patients  died  in  US.  By  2030,  annual  new  cancer  cases  will  rise  to  23.6M
worldwide1. It is vital and urgent to understand its mechanisms toward therapy. 
The current researches on cancer mechanism have mostly focused on protein-
coding  regions,  both  functional  genomics  and  genome  sequences,  and  have
revealed hundred proteins as key oncogenes and have identified thousands of
sequence  variations  across  different  cancer  types2–6.  Many  alterations  in
chromosomes and phenotypes have been observed7. Recently studies also have
explored cancer epigenetics mechanisms8 and have identified a certain groups of
noncoding RNAs associated with cancer development9 . These mechanisms have
helped to improve technologies on therapy10.  However, cancer is still an incurable
disease and drugs targeting molecular targets based on current mechanisms are
rarely  successful11,12,  suggesting  that  the  real  fundamental  mechanism  still
remains unclear. 
Here,  we  developed  a  computational  software  to  unearth  the  basic  cancer
mechanism hidden in the massive data from TCGA database.
Results
Noncoding RNAs serve as the deadliest regulators of cancers
To investigate the deadliest regulators for cancers, we needed a software that
could unbiasedly reveal the strongest genes corresponding to cancer death and a
data set  including all  types of  cancers.  Conventionally,   the  Cox proportional-
hazards  regression  model  (coxph)  has  been  widely  employed  to  find  cancer
genes13,  but it  lacks random sampling during regression, leading to inaccurate
estimations. Here, we developed an improved survival analysis software, referred
as  ISURVIVAL,  to  insert  stability-selection14 into  coxph  model  to  make  results
accurate (materials and methods). Implementing ISURVIVAL with julia computer
language also makes it much faster than current software. The data used in this
study was downloaded from The Cancer Genome Atlas (TCGA) public database,
which includes 11,574 RNAseq samples and clinic data for all 36 cancer types
(Table S1), which measured total 60,483 genes annotated with GRCh38.p2.v22
by TCGA (materials and methods). 
To select the deadliest genes, we applied ISURVIVAL to a data matrix containing
clinic  time and status  and each gene RNAseq data in  all  cancer samples  and
selected  the  top  428  significant  genes  with  absolute  coefficient  >1  and
pvalue<1.e-10 (materials and methods). We further ranked these 428 regulators
in basis of their absolute coefficients (coef), higher coefficient, more important in
regulating  cancer  death.  Among  428,   92% were  cancer  inducers  (coef  >  1,
HR>2.72), and only less than 8% were cancer repressors (coef< -1, HR< 0.37)
(Figure  1A).  Evermore,  all  top  30  regulators  were  100%   cancer  inducers.
Interestingly, processed-pseudogenes (p-pseudogenes)  occupied more than 80%
in these top 394 inducers (Figure 1B  left panel). At top 10 inducers,  6 (60%)
were  p-seudogenes,  and  top  1  was  PANDAR  (lincRNA)  (Figure  1B  right).
Consistently, previous studies also reported PANDAR as a caner inducer15. Among
cancer  repressors,  lincRNAs  and  antisense  RNA  occupied  40%  and  30%
respectively(Figure 1C). This suggested noncoding RNAs as the deadliest cancer
regulators and pseudo-genes as primary inducers and lincRNA and antisense RNA
as  key  repressors.  This  parallels  with  our  recent  study  on  cancer  mechanism
revealing noncoding RNAs as the core drivers for all types of cancer16.
Personal clinic variables account for variations of activated regulators 
Researchers on cancer DNA sequences have attempted to find the genes with
consensus variations across cancer types (disease types as described in  table
S1), but could not find any genes with more than 50% common mutations6. To test
the  consistence  of  gene  activation  across  cancer  types,  we  computed  the
coefficient of each gene in each cancer type, and found no consistence but high
variation  in  the regulator  activation.  Even the top 10 inducers  and repressors
identified above Figure 1, only <60% and <67% of inducers and repressors were
respectively activated as inducers (coef>0) and repressors (coef<0) across cancer
types (Figure 2A). For example, the top 1 inducer, PANDAR, did not always work
as an inducer, but as an inducer in only 57% cancer types and as a repressor in
the rest. 
We tried to find the reason for the activation variation, and examined the clinic
variable  effect  on  the  variations  of  top  30  regulators  by  using  canonical
correspondence analysis (CCA). Clinic variables significantly affect the activation
of genes. Among 7 character variables, sample type and alcohol affected most
(Figure 2B), while smoking and BMI as the digital variables accounted for most of
variances  (Figure  2C).  For  example,  PANDAR  was  positively  correlated  with
sample type and negative correlated to race (Figure 2B), significantly higher in
primary tumor (p=5.8e-9, t-test,  Figure S1) and Asian (p=0.00019, figure S2).
However, PANDAR did not seemed to respond very well cancer types and tissue
(Figure 2B).  Yet tissue type was used to classify cancer types.   This  at  least
partially explain its activation variation (only 57%) in current classification system-
disease type  . 
This observation above encouraged us to extend our CCA analysis to all genes
and all 11 clinic variables. The whole cancer genome was clearly separated into
three sections. The first positively affected by alcohol and smoking, the second by
site,  BMI  and  disease  type,  the  third  by  unidentified  factors  (Figure  2D).
Astonishingly,  alcohol  served  as  the  strongest  factor  altering  cancer  genome
activation, even stronger than smoking and BMI (Figure 2D).  This indicated that
the cancer genome activation is not only based on tissues as practiced by current
classification system, but, importantly, based on other personal clinical variables.
Therefore,  using  the  current  cancer  type  info  to  evaluate  the  activation  of
inducers and repressors as shown in Figure 2A could be misleading. Furthermore,
even the first 200 principal components (PCs) derived from principal component
analysis (PCA) only accounted for 60% variances (Figure 2E), indicating cancer
genome  activation  varying  with  unexpectedly  complicated  personal  clinic
variables.
Noncoding RNAs as universal drivers for cancers
Cancer regulator activation varies with complex factors as observed above. To
search the regulators universal for all types of cancers, we must concern personal
clinic variables. Here, we inserted the all 11 clinic variables and the first 200 PCs
as covariates into our ISURVIVAL to select regulators general for all cancers. The
top  64  significant  regulators  (p<0.05,  HR  >1.1  or  HR  <0.9)  included  65.6%
inducers (HR>1.1) and 34.4% repressors (HR<0.9)(Figure 3 A). Among inducers,
p-pseudogenes  dominated all profile and occupied 40% of top 10 (Figure 3B). As
expected, these inducers were consistently activated as inducers in most cancer
types, with RP11-335k5.2 activated in 83% cancer types (Figure 3C). The overall
percentage  of  inducer  activation  was  significantly  higher   than  previous  one
without concerning personal clinic variables shown in Figure 2A (p = 0.03151 and
0.08232 respectively for top 20 and top 10 inducers, t-test). This indicated these
pseudogene-dominated inducers as universal inducers of cancers. 
All  universal  repressors  were  also  noncoding  RNAs,  including  p-pseudogenes,
lincRNAs,  TEC,  antisense  and  sense_intronic  (Figure S3).  Together  suggested
noncoding RNAs as the universal drivers for all cancers. 
    
Noncoding  RNAs  serve  as  the  deadliest  hubs  in  cancer  regulatory
network
We  previously  established  a  cancer  regulatory  network  and  computed  the
centrality as top hubs in cancer genome. Here, we filtered these centrality with
survival data (p<0.01 and HR<0.9 or HR>1.1) and obtained the deadliest hubs.
More than 75% of top 491 hubs were inducers (Figure 4A) and all top 50 inducers
as p_pseudogenes (Figure 4B). Moreover, lincRNAs, antisense, p_ pseudogene
and  sense_intronic  dominated  the  top  50  repressors  (Figure  4C),  suggesting
noncoding RNAs as the deadliest centrality in cancer genome. 
Noncoding RNAs as cancer biomarkers
We further examined whether noncoding RNAs work as biomarkers to discriminate
cancer and normal  samples.  We used total  632 normal  samples  as  normal  to
discriminate cancer samples of each cancer type, and employed elastic-net with
stability-selection  to  select  biomarkers  for  each  cancer  type  (materials  and
methods).  Typically,  around  50  noncoding  RNAs  could  discriminate  cancer  vs
normal with rare error (Figure 5A). We used the top 50 noncoding RNAs in each
cancer type as biomarkers to calculate the discrimination accuracy by computing
AUC  (Area  Under  The  Curve)  of  ROC  (Receiver  Operating  Characteristics).
Beginning with top 2 biomarkers, the AUC of each cancer type reached >90%, and
with top 20 biomarkers, AUC reached stable state (>96%) for all cancer types
(Figure  5B).  This  indicated  noncoding  RNAs  can  be  used  as  biomarkers  to
discriminate cancer types.   
Discussion
Current researches on cancer drivers and mechanisms have focused on proteins
and protein-relevant DNA sequences2.  However,  recent observations suggested
most  of  these proteins  as  incorrect  targets,  which  were selected from current
mechanism studies 11. This suggests that the current mechanisms are misleading.
Here, we first time unearthed noncoding RNAs as the universal deadliest drivers
for  all  types  of  cancers.  Among noncoding  RNAs,  p-pseudogenes  work  as  the
primary cancer inducers. Noncoding RNAs have been reported as regulators for
cancer 17, and p-pseudogenes mutations have been found in cancers 18, but they
have not been reported as the key players replacing the protein spot in cancers.
Recent reports regarding noncoding RNAs have focused on lincRNA category but
have rarely demonstrated these pseudo-gene roles in cancer. Our findings here
have established pseudogenes as the most important cancer regulators, instead
of  proteins  as  conventionally  thought.  This  provides  a  novel  mechanism  and
targets for cancer research and therapy and eventually make cancer curable.
One of long standing puzzle hanging in cancer researches is the universality of
oncogenes.  Many  efforts   have  put  into  identifying  the  sequence  consensus
among  these  oncogenes,  but  no  oncogene  has  more  than  50  consensus
sequences across cancer types 6. Here, we revealed that the universal oncogenes
exist in noncoding RNAs after normalizing personal clinic variables. For example,
RP11-335k5.2 was consistently activated in 83% cancer types although current
cancer type classification is misleading as described below. 
Cancer types classified by tissue types have been used in cancer researched and
therapy development2, yet cancer genome activation does not respond very well
to  tissues  as  shown  in  the  present  study.  Surprisingly,  alcohol  contributes  to
cancer genome variations more than smoking, and these personal clinic variables
such as alcohol and smoking are more important than tissue types in altering
cancer  genome activation.  Therefore,  the  current  cancer  classification  system
may be misleading and should be reviewed to include personal variables to make
therapy efficiently. 
The current personal medicine on cancer has focused on personal DNA sequence
variation19 20,  but   personal  clinic  variables  such as  alcohol,  smoking and BMI
significantly  alter  cancer genome activation.  These personal  variables  may be
more important than personal DNA sequence variation in personal medicine. 
Overall, our finding based on personal clinic variables and gene expression data
has established noncoding RNAs as the most important inducers and repressors
for all cancers. This refreshes the concept on cancer mechanism and therapy.  
        
Figure legends
Figure  1.  The  deadliest  regulators  in  cancers.  A,  the  proportion  (%)  of
strongest inducers and repressors. B, gene categories of top deadliest inducers
(left  panel)  and top 10 inducers (right).  For  clear  illustration,  only  top 5 gene
categories were shown here and thereafter in this study. C, gene categories of top
repressors  (left) and top 10 repressors.
Figure 2. Personal clinic variables account for variations of cancer gene
expressions. A, heatmap shows gene coefficent variations of top 10 inducers
(upper)  and repressors  (bottom) across  30 individual  cancer types.   Each row
denotes a gene and each column as a cancer type.  For illustration propose, the
coefficient of a gene in a cancer type was set to 1 (coefficient >0, red color) or -1
(coefficient <0, blue color) or 0 (coefficient=0, white). The number following gene
symbol represents the frequency (%) of this gene in 30 cancer types as an inducer
(upper)  or  a  repressor  (bottom).  For  example,  0.6  in  ACTG1P11  =  18(red  as
inducer)/30. Left bar colors represent gene categories. In inducer panel(upper),
blue:  processed-pseudogenes  (p_pseudogene,  thereafter),  red:lincRNA,
green:protein_coding.  In  the  bottom  repressor,  pink:TEC,  red:antisense,
blue:linRNA,  green:p_pseudogene, brown: protein_coding (protein, thereafer). B,
Canonical correspondence analysis (CCA) plot of top 30 regulators and 7 character
clinic variables from all cancer samples. C,  CCA plot of top 30 regulators and 4
digital clinic variables from all cancer samples. D, CCA plot of all genes and total
11 clinic variables from all cancer samples. Cancer genome was clearly seperated
into 3 clusters based on clinic variables.  E, The cumulative variances accounted
by each principal  component (PC),  from PC1 to  PC200,  derived from principal
component analysis (PCA) of expressions of all genes and all cancer samples.  
Figure  3.  Universal  cancer  inducers  and  repressors. A,  proportion  of
universal inducers and repressors. B, Gene categories of inducers. C, coefficient
heatmap of top 10 universal inducers in 30 cancer types. Left bar colors denote
gene categories, red:antisense, brown:p-pseudogene, blue:lincRNA, pink:protein,
green:miRNA, yellow:snRNA.   
Figure 4. Distribution of inducers and repressors inferred from genome
regulatory network. A, proportion of top inducers and repressors derived from
network  centrality.  B,  Gene  categories  of  inducers.  C,  gene  categories  of
repressors.
Figure 5. noncoding RNAs as biomarkers to discriminate 30 cancer types.
A, a typical cross-validation curve of noncoding RNAs as biomarkers. When  total
around  50  noncoding  RNAs  were  selected,  the   mean  cross-validated  error
reached minimum, and this corresponding lambda was selected as lambda.min for
biomarker  selections  for  all  30  cancer  types.  B,  AUC  of  noncoding  RNAs  as
biomarkers  to  discriminate  30  cancer  types.  When  10  noncoding  RNAs  as
biomarkers, AUCs for most cancer types have not reached stable states, but when
20  noncoding  RNAs  were  selected  as  biomarkers,  all  AUCs  were  stable,  with
AUC>0.96.   
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